<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic migraine</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic migraine</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic migraine</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ivan Garza, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd J Schwedt, MD, MSCI</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Elizabeth Robertson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic daily headache is a descriptive term that encompasses several different specific headache diagnoses characterized by frequent headaches. Primary chronic daily headache disorders with individual headaches of long duration (ie, four hours or more) include chronic migraine, chronic tension-type headache, hemicrania continua, and new daily persistent headache.</p><p>This topic will discuss chronic migraine. Other types of chronic daily headache are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/3333.html" rel="external">"Chronic daily headache: Associated syndromes, evaluation, and management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of migraine centers on the trigeminovascular system. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Pathophysiology'</a>.)</p><p>Although the pathophysiology of the transformation from episodic to chronic migraine is not well understood, it is hypothesized that atypical pain processing, cortical hyperexcitability, neurogenic inflammation, and central sensitization are involved [<a href="#rid1">1,2</a>]. Furthermore, in patients with migraine, functional and structural alterations in the brain have been identified that correlate with longer disease duration and increased headache frequency [<a href="#rid3">3,4</a>]. However, it is not clear whether these alterations lead to chronic migraine. They may be simply markers of transformation or secondary effects from frequent migraine attacks.</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Chronic migraine affects approximately 2 percent of the world population [<a href="#rid5">5</a>]. It causes significant reductions in quality of life and is even more disabling than episodic migraine [<a href="#rid6">6-9</a>]. In addition, chronic migraine results in enormous expense to society. In the United States, the direct and indirect costs of migraine are estimated to be more than 20 billion dollars annually, and a significant proportion of this cost is attributable to chronic migraine [<a href="#rid10">10</a>].</p><p>Some patients with an episodic migraine pattern (&lt;15 headache days a month) transition to a chronic migraine pattern (≥15 headache days a month), a transition that has been called "transformation" and "chronification" [<a href="#rid11">11</a>]. Among patients with episodic migraine, transformation to chronic migraine occurs in approximately 3 percent per year [<a href="#rid12">12</a>]. Those with more comorbidities, such as respiratory, cardiovascular, digestive, psychiatric, central nervous system, and pain disorders, have an increased likelihood for transformation to chronic migraine [<a href="#rid13">13</a>].</p><p>Nonmodifiable risk factors for the transformation from episodic to chronic migraine include the following [<a href="#rid1">1,14-20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Female sex</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic makeup</p><p class="bulletIndent1"><span class="glyph">●</span>History of head or neck injury</p><p class="bulletIndent1"><span class="glyph">●</span>Low education level</p><p class="bulletIndent1"><span class="glyph">●</span>Low socioeconomic status</p><p class="bulletIndent1"><span class="glyph">●</span>Stressful life events (eg, divorce, job loss)</p><p class="bulletIndent1"><span class="glyph">●</span>Younger age</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of cutaneous allodynia</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid pain disorders</p><p></p><p>Potentially modifiable risk factors for this transformation include [<a href="#rid1">1,14-18,20-25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher baseline headache frequency</p><p class="bulletIndent1"><span class="glyph">●</span>High frequency use or overuse of abortive headache medications</p><p class="bulletIndent1"><span class="glyph">●</span>Depression</p><p class="bulletIndent1"><span class="glyph">●</span>Habitual snoring</p><p class="bulletIndent1"><span class="glyph">●</span>High caffeine consumption</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Low efficacy of acute migraine treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent, frequent nausea</p><p class="bulletIndent1"><span class="glyph">●</span>Asthma</p><p></p><p>A 2020 meta-analysis of 11 cohort studies found the strongest risk factors for transformation to chronic migraine were higher baseline headache frequency, depression, cutaneous allodynia, and medication overuse [<a href="#rid25">25</a>]. Further study is needed to determine if altering modifiable risk factors decreases the rate of transformation from episodic to chronic migraine.</p><p>Patients who develop chronic migraine may revert to episodic migraine, as discussed below. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H319633283"><span class="h2">Headache</span><span class="headingEndMark"> — </span>Many patients with chronic migraine have daily or near-daily mild-to-moderate intensity headaches and mild migrainous features with superimposed severe intensity headaches with more prominent migrainous features such as photophobia, phonophobia, osmophobia, nausea, vomiting, and cutaneous allodynia (ie, the perception of pain produced by innocuous stimulation of normal skin). (See  <a class="medical medical_review" href="/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Comorbid conditions</span><span class="headingEndMark"> — </span>In observational studies, patients with chronic migraine have a high frequency of comorbid psychiatric disorders, sleep disorders, respiratory disorders, fatigue, cardiovascular disorders, other types of pain, and gastrointestinal symptoms; migraine is also associated with a small increase in the absolute risk of ischemic stroke [<a href="#rid26">26-35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, psychiatric comorbidities among 152 patients with chronic migraine included major depression, dysthymia, panic disorder, and generalized anxiety disorder, observed in 57, 11, 30, and 8 percent, respectively [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 63 patients with chronic migraine, two-thirds meet criteria for chronic fatigue syndrome [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a report of 101 patients with chronic migraine, the diagnostic criteria for fibromyalgia were fulfilled by 36 percent [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a sample of 1283 migraineurs who presented for evaluation to a tertiary headache clinic, patients with chronic migraine slept less than those with episodic migraine and were more likely to report difficulty falling and staying asleep [<a href="#rid30">30</a>]. In a study of 12,810 patients with migraine, those with chronic migraine (9 percent) were more likely to report poor sleep quality, snoring, and somnolence [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 150 patients with chronic migraine complicated by probable medication overuse headache, the most common comorbidities were psychiatric and gastrointestinal, identified in 76 and 43 percent, respectively [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Accumulating evidence supports an association between migraine, particularly migraine with aura, and ischemic stroke risk. However, the absolute increase in the risk of stroke is small. Migraine may also be associated with an increased risk for other forms of cardiovascular disease such as myocardial infarction. These relationships are discussed separately. (See  <a class="medical medical_review" href="/d/html/3344.html" rel="external">"Migraine-associated stroke: risk factors, diagnosis, and prevention"</a>.)</p><p></p><p>Recognition and treatment of these comorbidities can result in improved health, greater quality of life, and may potentially result in higher migraine treatment success rates.</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of chronic migraine depends upon a consistent clinical history.</p><p>The diagnostic criteria for chronic migraine requires the presence of headache for 15 or more days per month for more than three months, with the features of migraine headache present on at least eight days per month  (<a class="graphic graphic_table graphicRef56064" href="/d/graphic/56064.html" rel="external">table 1</a>) [<a href="#rid37">37</a>]. These criteria allow for the inclusion of migraine headaches that are treated early after the onset, prior to the development of typical migraine characteristics, when they may resemble tension-type headaches.</p><p>Chronic migraine  (<a class="graphic graphic_table graphicRef56064" href="/d/graphic/56064.html" rel="external">table 1</a>) must be differentiated from other forms of chronic daily headache, such as chronic tension-type headache  (<a class="graphic graphic_table graphicRef68892" href="/d/graphic/68892.html" rel="external">table 2</a>), hemicrania continua  (<a class="graphic graphic_table graphicRef62652" href="/d/graphic/62652.html" rel="external">table 3</a>), new daily persistent headache  (<a class="graphic graphic_table graphicRef76010" href="/d/graphic/76010.html" rel="external">table 4</a>), and secondary headaches. (See  <a class="medical medical_review" href="/d/html/3333.html" rel="external">"Chronic daily headache: Associated syndromes, evaluation, and management"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The treatment of chronic migraine should focus on prophylactic therapy while avoiding migraine triggers and limiting the use of acute headache medications that are associated with medication overuse headache [<a href="#rid1">1,35</a>]. Prophylactic interventions may include pharmacotherapy, behavioral therapy, physical therapy, and other strategies. Management often requires the simultaneous use of these different therapeutic modalities.</p><p>Identification and treatment of comorbid disorders is also important. (See <a class="local">'Comorbid conditions'</a> above.)</p><p>The use of acute headache medications should be limited to minimize the risk of medication overuse headache, but severe superimposed migraine attacks are treated in the same manner as episodic migraine attacks. (See  <a class="medical medical_review" href="/d/html/3347.html" rel="external">"Acute treatment of migraine in adults"</a> and  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>.)</p><p>Patients and clinicians should have realistic treatment expectations with regard to chronic migraine. The overall goal is control of headaches as opposed to eradication. It is reasonable to expect reductions in headache frequency, severity, duration, and/or headache-related disability with a well-considered treatment plan.</p><p class="headingAnchor" id="H8"><span class="h2">Pharmacotherapy</span><span class="headingEndMark"> — </span>Many prophylactic medications used for episodic migraine are also used for the prevention of chronic migraine based on efficacy for prevention of episodic migraine, tolerability, insurance coverage, and cost  (<a class="graphic graphic_table graphicRef141580" href="/d/graphic/141580.html" rel="external">table 5</a>). Preventive medications for chronic migraine treatment are less well studied than they are for episodic migraine. In addition, some trials evaluating treatment of chronic migraine are limited by one or more methodologic problems, such as small size, concomitant use of other prophylactic medications, and/or lack of a specific headache diagnosis [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">First-line agents</span><span class="headingEndMark"> — </span>We suggest starting with one of the first-line agents, based on individual patient factors. (See <a class="local">'Choosing an agent'</a> below.)</p><p>First-line prophylactic medications for chronic migraine include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">Propranolol</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproic acid</a> and its derivatives (for males and for females who do not have childbearing potential)</p><p></p><p>It is expected that up to 50 percent of patients treated with one of these medications will have at least a 50 percent reduction in the frequency of headaches after three months of treatment, given adequate doses. However, side effects are common and may limit the use of these prophylactic agents.</p><p><a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> has at least two randomized placebo-controlled trials supporting its use for chronic migraine prophylaxis [<a href="#rid39">39-41</a>]. There is lower-quality evidence for chronic migraine prophylaxis with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a> and derivatives, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">tizanidine</a>, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>, <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a>, and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid42">42-50</a>]. Nevertheless, some of these agents (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, amitriptyline) are considered first line for chronic migraine treatment based upon clinical experience and strong data supporting their benefit in episodic migraine.</p><p class="headingAnchor" id="H10"><span class="h3">Second- and third-line agents</span><span class="headingEndMark"> — </span>We suggest the use of second-line agents for the prevention of chronic migraine for patients with a contraindication to or inadequate response (after at least eight weeks at a therapeutic dose) of two or more first-line drugs, in agreement with guidelines [<a href="#rid51">51</a>]. We use third-line agents when first-line and second-line agents have failed or are contraindicated.</p><p>In addition, alternative therapies may be used as adjunctive therapy when initial treatment provides partial but suboptimal benefit. These recommendations are based upon our clinical experience. Like first-line agents, the choice among the second- and third-line therapies depends upon individual patient factors. (See <a class="local">'Choosing an agent'</a> below.)</p><p>For patients with chronic migraine that is refractory to adequate trials of first-line agents, several other drugs are potential alternatives, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Second-line agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">OnabotulinumtoxinA</a></p><p class="bulletIndent2"><span class="glyph">•</span>Calcitonin gene-related peptide (CGRP) antagonists (<a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">erenumab</a>, <a class="drug drug_general" data-topicid="119043" href="/d/drug information/119043.html" rel="external">fremanezumab</a>, <a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">galcanezumab</a>, <a class="drug drug_general" data-topicid="127182" href="/d/drug information/127182.html" rel="external">eptinezumab</a>, <a class="drug drug_general" data-topicid="133172" href="/d/drug information/133172.html" rel="external">atogepant</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Occipital nerve block (ONB)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">Venlafaxine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a></p><p class="bulletIndent2"><span class="glyph">•</span>Other beta blockers (<a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="9672" href="/d/drug information/9672.html" rel="external">nadolol</a>, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a></p><p class="bulletIndent2"><span class="glyph">•</span>Magnesium</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">Riboflavin</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8670" href="/d/drug information/8670.html" rel="external">Candesartan</a></p><p class="bulletIndent2"><span class="glyph">•</span>Other tricyclic antidepressants (<a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>, <a class="drug drug_general" data-topicid="9832" href="/d/drug information/9832.html" rel="external">protriptyline</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Third-line agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Feverfew</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">Tizanidine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">Cyproheptadine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">Zonisamide</a></p><p></p><p>There is evidence from randomized placebo-controlled trials supporting the efficacy of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a>, CGRP antagonists, and occipital nerve blocks for chronic migraine. (See <a class="local">'Botulinum toxin'</a> below and <a class="local">'CGRP antagonists'</a> below and <a class="local">'Occipital nerve block'</a> below.)</p><p>The effectiveness of the remaining second-line medications for episodic and chronic migraine is uncertain, as most have been studied only on a limited basis. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'Calcium channel blockers'</a> and  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'Other agents'</a>.)</p><p class="headingAnchor" id="H2129044079"><span class="h3">Evidence of efficacy</span></p><p class="headingAnchor" id="H2469312493"><span class="h4">Botulinum toxin</span><span class="headingEndMark"> — </span>Initial randomized trials evaluating botulinum toxin injection for chronic migraine (≥15 headache days a month) or chronic daily headache yielded mixed results [<a href="#rid52">52-54</a>], but the findings from two relatively large 24-week multicenter randomized controlled trials (PREEMPT 1 AND PREEMPT 2) suggest that <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> is effective for the treatment of chronic migraine [<a href="#rid55">55,56</a>].</p><p>In PREEMT 1, a trial of 679 patients with chronic migraine, the reduction in headache episodes from baseline to week 24 was similar in treatment and placebo groups (-5.2 versus -5.3 days), but patients assigned to <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> had greater improvements in secondary outcome measures, including fewer headache days and fewer migraine days, than those assigned to placebo [<a href="#rid55">55</a>].</p><p>In PREEMT 2, a trial that included 705 patients with chronic migraine, patients assigned to <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> had a greater reduction in the number of monthly headache days than those assigned placebo (9 versus 7 days) [<a href="#rid56">56</a>]. Improvements in secondary outcome measures were also greater with onabotulinumtoxinA.</p><p>Pooled analyses of data from the PREEMPT 1 and PREEMPT 2 trials, which together enrolled 1384 adults, found differences favoring <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> for a decrease in the frequency of headache days relative to baseline (the same primary outcome as PREEMPT 2) and for nearly all secondary outcomes except the frequency of acute headache pain medication intake [<a href="#rid57">57,58</a>]. The rate of treatment discontinuation due to adverse events was low, but it was higher for onabotulinumtoxinA than for placebo (3.8 versus 1.2 percent). In addition, the placebo response was high in these trials, and the difference between onabotulinumtoxinA injection and placebo for many of the outcomes was modest, even if statistically significant [<a href="#rid55">55-57</a>]. A meta-analysis of observational data similarly found onabotulinumtoxinA was associated with reductions in the number of monthly headache days and other headache outcome measures when assessed at 24 and 52 weeks [<a href="#rid59">59</a>].</p><p>Overall, these and other data support the utility of botulinum toxin injection as moderately effective for the treatment of chronic migraine [<a href="#rid60">60-62</a>]. However, several factors have led us to consider it as second-line therapy. These factors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Administration must be performed in a clinical setting, by an experienced clinician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cost is high compared with many oral agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restrictive policies of some insurance companies limit reimbursement for <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> to patients who fail or are unable to tolerate other prophylactic medications.</p><p></p><p>In addition, some patients report a "wear-off" period days to weeks before the next <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> injections are due, a phenomenon that has not been well studied. During this period, patients often report an increase in headache frequency. In a prospective report of 24 patients, the wear-off phenomenon commenced around the eighth week post injection [<a href="#rid63">63</a>]. In a retrospective study of 143 patients, wear-off occurred in 63 percent, commonly two to four weeks before subsequent injections were due [<a href="#rid64">64</a>]. During this wear-off period, bridge therapy with craniocervical peripheral nerve blocks, intramuscular <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a>, and other treatments can be used [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H1362475726"><span class="h4">CGRP antagonists</span><span class="headingEndMark"> — </span>Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) ligand or its receptor are available for migraine prevention  (<a class="graphic graphic_table graphicRef141581" href="/d/graphic/141581.html" rel="external">table 6</a>). Agents used for prevention of chronic migraine include <a class="drug drug_general" data-topicid="127182" href="/d/drug information/127182.html" rel="external">eptinezumab</a>, <a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">erenumab</a>, <a class="drug drug_general" data-topicid="119043" href="/d/drug information/119043.html" rel="external">fremanezumab</a>, <a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">galcanezumab</a>, and <a class="drug drug_general" data-topicid="133172" href="/d/drug information/133172.html" rel="external">atogepant</a>. However, given their high cost and insurance coverage stipulations, we consider these CGRP antagonists as second line, even though there is high-quality evidence for their efficacy (modest) and tolerability. (See <a class="local">'Pharmacotherapy'</a> above and  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'CGRP antagonists'</a>.)</p><p>CGRP is a therapeutic target in migraine because of its role in mediating trigeminocervical pain transmission and the vasodilatory component of neurogenic inflammation. (See  <a class="medical medical_review" href="/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Role of calcitonin gene-related peptide'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fremanezumab</strong> – A randomized controlled trial of 1130 adults with chronic migraine evaluated <a class="drug drug_general" data-topicid="119043" href="/d/drug information/119043.html" rel="external">fremanezumab</a>, which selectively binds to CGRP [<a href="#rid65">65</a>]. The trial randomly assigned subjects in a 1:1:1 ratio to subcutaneous injections of fremanezumab quarterly, fremanezumab monthly, or matching placebo. At 12 weeks, fremanezumab was modestly effective for reducing the average number of headache days per month (-4.3 days for the fremanezumab quarterly group, -4.6 days for fremanezumab monthly group, and -2.5 days for the placebo group). The corresponding absolute risk reduction (ARR) values for the fremanezumab quarterly and monthly groups were -1.8 and -2.1 days. Patients receiving placebo and newly enrolled patients were subsequently randomized to quarterly or monthly injections, and all patients were followed for another nine months. At 12 months, the reduction in baseline migraine burden was sustained with fremanezumab [<a href="#rid66">66</a>]. Subjects assigned to quarterly and monthly injections reported 7.2 and 8.0 fewer migraine days per month, respectively. Another trial of fremanezumab demonstrated its modest efficacy among individuals with chronic migraine for whom two to four classes of migraine preventive medication had failed within the prior 10 years [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'CGRP antagonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erenumab</strong> – A randomized 12-week placebo-controlled trial of over 600 patients with chronic migraine evaluated subcutaneous <a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">erenumab</a>, which inhibits the CGRP receptor [<a href="#rid68">68</a>]. Erenumab 70 mg and 140 mg given by subcutaneous injection every four weeks reduced monthly migraine days versus placebo (both doses -6.6 days, versus -4.2 days for placebo; ARR -2.4 days). Results from a one-year open-label extension phase suggested that long-term efficacy was sustained [<a href="#rid69">69</a>]. Other studies have reported that erenumab is associated with improvements in quality of life and reductions in headache-related disability and appears to be effective even when medication overuse is present and when prior migraine preventive medications have failed [<a href="#rid70">70-72</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">Erenumab</a> appears to be effective for patients with chronic migraine with and without aura. In a secondary analysis of four clinical trials involving 667 patients with chronic migraine, erenumab 70 mg or 140 mg provided greater reductions in monthly migraine days by 12 weeks compared with placebo. The effectiveness of erenumab over placebo was also sustained when results, as assessed by the proportion of patients reporting at least a 50 percent reduction in the number of monthly migraine days by 12 weeks, were stratified among those with chronic migraine with (42 percent for 70 mg, 46 percent for 140 mg, 24 percent for placebo) and without aura (39 percent for 70 mg and 140 mg, 23 percent for placebo) [<a href="#rid73">73</a>]. Adverse effects were mild and similar between groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Galcanezumab</strong> – Another controlled trial of 1113 adults with chronic migraine evaluated <a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">galcanezumab</a>, which targets the CGRP ligand [<a href="#rid74">74</a>]. Participants were randomly assigned to monthly subcutaneous injections in a 1:1:2 ratio of galcanezumab 120 mg (with a 240 mg loading dose), galcanezumab 240 mg, or placebo. At three months, reductions in the mean number of monthly migraine headache days were greater for galcanezumab 120 mg and galcanezumab 240 mg compared with placebo (-4.8 and -4.2, versus -2.7 for placebo). The corresponding ARR values for the galcanezumab 120 mg and 240 mg groups were -2.1 and -1.5 days. Galcanezumab is also effective for patients who have not responded to prior preventive therapies [<a href="#rid75">75,76</a>]. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'CGRP antagonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eptinezumab</strong> – A randomized trial of over 1000 patients with chronic migraine evaluated intravenous <a class="drug drug_general" data-topicid="127182" href="/d/drug information/127182.html" rel="external">eptinezumab</a>, which targets the CGRP ligand, given at day 0 and week 12. At 12 weeks, the mean number of monthly migraine headache days was reduced with eptinezumab 100 mg (-7.7 days; ARR -2.1 days) and 300 mg (-8.2 days; ARR -2.6 days), compared with placebo (-5.6 days) [<a href="#rid77">77</a>]. At 24 weeks, the reduction in mean monthly migraine headache days was sustained with eptinezumab 100 mg (-8.2 days; ARR -2.0 days) and 300 mg (-8.8 days; ARR -2.6 days) compared with placebo (-6.2 days) [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atogepant</strong> – <a class="drug drug_general" data-topicid="133172" href="/d/drug information/133172.html" rel="external">Atogepant</a> is a small-molecule CGRP antagonist available by oral administration. A clinical trial evaluated 778 patients with chronic migraine who were randomized to atogepant or placebo [<a href="#rid79">79</a>]. The baseline frequency of migraine was a mean of 19 monthly migraine days. At 12-week follow-up, the mean reduction in baseline monthly migraine days was greater for patients assigned to atogepant 60 mg once daily or 30 mg twice daily than those assigned to placebo (-6.9 and -7.5 versus -5.1 days). In addition, the proportion of patients who achieved ≥50 percent reduction of monthly migraine days was also higher with atogepant 60 mg once daily and atogepant 30 mg twice daily (41 and 43 versus 26 percent). Treatment was well tolerated with the most common adverse effects being nausea and constipation. Atogepant was approved for use in patients with chronic migraine by the FDA in 2023 [<a href="#rid80">80</a>].</p><p></p><p>The CGRP monoclonal antibodies were generally well tolerated in these clinical trials. Injection site reactions and hypersensitivity reactions were the most commonly observed adverse effects. Constipation and hypertension, at times causing serious complications, have been observed with <a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">erenumab</a>. Cases of angioedema and anaphylaxis have also been reported [<a href="#rid81">81,82</a>]. Potential adverse effects of the CGRP monoclonal antibodies related to pregnancy or breastfeeding are unknown and thus should be avoided.</p><p>CGRP antagonists may also provide additional benefit to patients with chronic migraine with a partial response to <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> [<a href="#rid83">83</a>]. In a retrospective study of 153 patients with chronic migraine treated with onabotulinumtoxinA, 73 percent (111 patients) reported a reduced headache burden after adding a CGRP antagonist [<a href="#rid84">84</a>]. There were no serious adverse events. In another retrospective study of 78 patients with chronic migraine, the addition of <a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">erenumab</a> was associated with a reduction of approximately 7 monthly headache days at one month from a baseline of 23 mean monthly headache days on onabotulinumtoxinA alone [<a href="#rid85">85</a>]. These results were sustained at 60 and 90 days. Clinical trials are necessary to confirm results from these retrospective studies [<a href="#rid83">83,85</a>].</p><p>The use of CGRP antagonists for the prevention of episodic migraine is discussed separately. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'CGRP antagonists'</a>.)</p><p class="headingAnchor" id="H1360555310"><span class="h4">Occipital nerve block</span><span class="headingEndMark"> — </span>Local injection of an anesthetic agent often used for occipital neuralgia has also been used for some headache disorders. ONB may modulate nociceptive activity in afferent pathways that converge on the trigeminal ganglion and reduce the likelihood of developing headache and migraine attacks. In a small trial of 44 patients with chronic migraine who received bilateral greater occipital nerve injections every four weeks for 12 weeks, those who received <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> 40 mg had a greater mean reduction in the number of migraine days at weeks 9 to 12 than patients who received placebo (least squares mean reduction -4.7 days, 95% CI -7.7 to -1.7) [<a href="#rid86">86</a>]. In addition, patients who received lidocaine injection were likelier to report ≥50 percent reduction in headache days (41 versus 9 percent). Adverse events were mild and transient and occurred at similar rates in treatment and placebo groups. Most common events were injection site bleeding and pain.</p><p>ONB may also have benefit as adjunctive therapy for patients treated with pharmacotherapy. In a clinical trial that assessed the effect of adding ONB to pharmacotherapy with <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, 125 patients with chronic migraine were randomized to receive topiramate titrated up to 50 mg twice daily as monotherapy, topiramate with bilateral ONB consisting of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> 40 mg and <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 80 mg followed by monthly ONB with lidocaine for two months, or topiramate with bilateral ONB consisting of lidocaine 40 mg for three months [<a href="#rid87">87</a>]. At three-month follow-up, the groups who received ONB both with and without initial glucocorticoid had greater reductions in monthly migraine days than those who received topiramate monotherapy (-9.6 and -10.1 versus -7.3 days). The responder rate, defined as achieving ≥50 percent reduction in mean monthly headache days, was also higher for patients who received additional ONB with or without glucocorticoid (71 and 62 versus 39 percent). The most common adverse events likely attributable to the ONBs included local site bleeding and swelling as well as alopecia in those receiving glucocorticoid.</p><p class="headingAnchor" id="H11"><span class="h3">Choosing an agent</span><span class="headingEndMark"> — </span>The choice of specific prophylactic agent for either episodic or chronic migraine depends upon individual patient factors, including the presence of comorbid conditions such as medical disorders, psychiatric disorders, sleep disorders, fatigue, other types of pain, and gastrointestinal complaints  (<a class="graphic graphic_table graphicRef141580" href="/d/graphic/141580.html" rel="external">table 5</a>). As an example, tricyclics or other antidepressants may be preferred for patients who are depressed or are prone to depression. On the other hand, beta blockers may be preferred for patients with hypertension. However, with some preventive agents, the doses used to treat migraine are insufficient to treat comorbid conditions. Thus, dosing may need to be adjusted if the intent is to treat a comorbid condition.</p><p>Regardless of the drug chosen, application of certain principles may improve the success rate of prophylactic migraine therapy and reduce complications:</p><p class="bulletIndent1"><span class="glyph">●</span>Start oral drugs at a low dose and increase gradually.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Give the chosen medication an adequate trial:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For oral medications, at least eight weeks at goal dose range [<a href="#rid88">88</a>]; the typical dosing of oral medications for migraine prophylaxis is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For botulinum toxin, a minimum of three sets of injections separated by 12 weeks, since a substantial number of patients who do not respond to the first injection respond to the second or third one [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For monoclonal antibodies targeting the CGRP ligand or its receptor, a minimum of three months for those administered monthly and six months after the start of quarterly treatments [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid overuse of acute headache medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> for females of childbearing potential unless it is essential to management and alternative therapies are not appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Address patient expectations and preferences.</p><p></p><p>These points are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'Principles of preventive therapy'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Nonpharmacologic therapy</span><span class="headingEndMark"> — </span>Nonpharmacologic forms of therapy may be useful for the treatment of chronic migraine. Modalities include behavioral therapy (eg, biofeedback, cognitive-behavioral therapy, stress management, relaxation therapy), physical therapy (eg, exercise, heat, cold packs), and neurostimulation. In addition, therapeutic lifestyle changes (eg, good sleep hygiene, routine meal schedules, regular exercise) and avoidance of migraine triggers are often advocated for patients with chronic migraine [<a href="#rid35">35</a>]. However, there is a paucity of high-quality studies examining the role of nonpharmacologic interventions specifically for chronic migraine.</p><p class="headingAnchor" id="H13"><span class="h3">Avoidance of migraine triggers</span><span class="headingEndMark"> — </span>Patients with chronic migraine are more likely to have headaches triggered by stress, not eating, odors, neck pain, smoke, sleeping late, and exercise than patients with episodic migraine [<a href="#rid90">90</a>]. These are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Precipitating and exacerbating factors'</a>.)</p><p>Avoidance of specific migraine triggers may reduce the frequency of headaches in patients with chronic migraine. Of course, patients with continuous headaches are less likely to be able to determine specific migraine triggers than those who have episodic headaches.</p><p class="headingAnchor" id="H14"><span class="h3">Behavioral and physical therapy</span><span class="headingEndMark"> — </span>In agreement with guidelines for migraine headache (mainly based upon studies of episodic migraine) from the American Academy of Neurology (AAN) published in 2000 [<a href="#rid91">91</a>], we suggest the use of behavioral therapy for migraine prevention. Options include relaxation training, thermal biofeedback combined with relaxation training, electromyographic biofeedback, or cognitive-behavioral therapy. The choice among these interventions should be individualized according to factors that include clinician familiarity, local availability and expertise, and patient preference.</p><p>In our clinical experience, physical therapy may be useful for the treatment of chronic migraine in patients who have constant muscle tension or in those who report onset of muscle tension preceding migraine headaches. Of note, the AAN guidelines concluded that evidence-based recommendations could not be made regarding the use of hypnosis, acupuncture, transcutaneous electrical nerve stimulation, chiropractic or osteopathic cervical manipulation, occlusal adjustment, or hyperbaric oxygen [<a href="#rid91">91</a>].</p><p>Both behavioral therapy and physical therapy may be combined with each other and/or with preventive drug therapy [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H634848644"><span class="h3">Neurostimulation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transcranial magnetic stimulation</strong> – Limited observational evidence suggests that single-pulse transcranial magnetic stimulation (sTMS) may be effective for migraine prevention, as reviewed separately [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'Neuromodulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transcutaneous supraorbital nerve stimulation</strong> – There is evidence from at least one small randomized-controlled trial that supraorbital transcutaneous electrical nerve stimulator is beneficial for migraine prevention, as reviewed elsewhere [<a href="#rid94">94</a>] (see  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'Neuromodulation'</a>). Evidence from a small open-label study suggests benefit for some patients with chronic migraine as well [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occipital nerve stimulation</strong> – There are inconsistent data from small randomized trials regarding the benefit of occipital nerve stimulation for the treatment of chronic migraine [<a href="#rid96">96,97</a>]. In the largest trial, there was no significant difference at 12 weeks for the primary endpoint, the percentage of patients who had a ≥50 percent reduction in mean daily pain score in the active compared with the control group [<a href="#rid97">97</a>]. However, there were statistically significant if modest improvements with active stimulation for a number of secondary endpoints, including the percentage of patients with a ≥30 percent reduction in mean daily pain score, and reduction in the mean number of headache days and migraine-related disability. The findings from these reports are limited by concerns about blinding in the control (sham treatment) groups, given that active treatment causes paresthesia, and relatively high rates of complications, including lead migration in 14 to 24 percent of subjects [<a href="#rid96">96-99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninvasive</strong> <strong>vagus nerve stimulation</strong> – A noninvasive vagus nerve stimulation (nVNS) device is approved by the US FDA for migraine prevention in adult patients. However, the efficacy of nVNS for migraine prevention is not established. In two randomized controlled trials, the mean reduction in the number of headache days per month was greater for patients assigned to nVNS compared with sham stimulation, but the difference was modest and did not reach statistical significance [<a href="#rid100">100,101</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Chronic migraine may revert to episodic migraine over time in 26 to 70 percent of patients [<a href="#rid102">102,103</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The largest study, conducted by mailed questionnaire, followed 383 respondents with chronic migraine [<a href="#rid103">103</a>]. After two years, chronic migraine had remitted to either low-frequency episodic migraine (≤9 headache days/month), other episodic headache, or no headache in 26 percent. Predictors of remission were lower baseline headache frequency and absence of cutaneous allodynia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another report evaluated 136 patients with chronic migraine who presented to a specialty headache clinic and were followed for one year [<a href="#rid102">102</a>]. Reversion to episodic migraine from transformed migraine was observed in 95 patients (70 percent). Predictors of reversion included complete withdrawal of overused medications, compliance with prophylactic medication regimens, and regular physical exercise.</p><p></p><p>Some patients have a pattern of moving in and out of a chronic migraine state over time [<a href="#rid1">1,20,104</a>].</p><p class="headingAnchor" id="H4104510334"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H3063045901"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/112403.html" rel="external">"Patient education: Migraines in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/734.html" rel="external">"Patient education: Migraines in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Chronic migraine occurs when patients with an episodic migraine pattern transition to a pattern of ≥15 headache days a month. Many patients with chronic migraine have daily or near-daily headaches of mild to moderate severity. Superimposed on this baseline are exacerbations of pain with more prominent migrainous features. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">Patients with chronic migraine have a high frequency of comorbid psychiatric disorders, sleep disorders, fatigue, respiratory disorders, other types of pain, gastrointestinal complaints, cerebrovascular disease, and cardiovascular disease. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of chronic migraine depends upon a consistent clinical history  (<a class="graphic graphic_table graphicRef56064" href="/d/graphic/56064.html" rel="external">table 1</a>). Chronic migraine also must be differentiated from other forms of long-duration primary chronic daily headache, including chronic tension-type headache  (<a class="graphic graphic_table graphicRef68892" href="/d/graphic/68892.html" rel="external">table 2</a>), hemicrania continua  (<a class="graphic graphic_table graphicRef62652" href="/d/graphic/62652.html" rel="external">table 3</a>), and new daily persistent headache  (<a class="graphic graphic_table graphicRef76010" href="/d/graphic/76010.html" rel="external">table 4</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of chronic migraine should focus on prophylactic therapy and avoidance of acute headache medication overuse. Prophylactic interventions may include pharmacotherapy, behavioral therapy, physical therapy, lifestyle modification (good sleep hygiene, routine meal schedules, regular exercise), neuromodulation, and avoidance of migraine triggers. Management often requires the simultaneous use of these different therapeutic modalities. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacotherapy</strong> – The choice among migraine prophylactic agents depends upon individual patient factors and comorbid conditions  (<a class="graphic graphic_table graphicRef141580" href="/d/graphic/141580.html" rel="external">table 5</a>). (See <a class="local">'Pharmacotherapy'</a> above and <a class="local">'Choosing an agent'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with chronic migraine who desire pharmacologic treatment, we suggest a trial with one of the first-line prophylactic migraine medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). First-line prophylactic agents are <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, and <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>; <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a> and its derivatives are also first line for those who do not have childbearing potential. (See <a class="local">'First-line agents'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with chronic migraine who have failed treatment with at least two first-line agents, options include <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> injections, a CGRP antagonist (eg, <a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">erenumab</a>, <a class="drug drug_general" data-topicid="119043" href="/d/drug information/119043.html" rel="external">fremanezumab</a>, <a class="drug drug_general" data-topicid="119169" href="/d/drug information/119169.html" rel="external">galcanezumab</a>, <a class="drug drug_general" data-topicid="127182" href="/d/drug information/127182.html" rel="external">eptinezumab</a>, or <a class="drug drug_general" data-topicid="133172" href="/d/drug information/133172.html" rel="external">atogepant</a>), <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, other beta blockers, <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, magnesium, <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a>, <a class="drug drug_general" data-topicid="8670" href="/d/drug information/8670.html" rel="external">candesartan</a>, other tricyclic antidepressants, or occipital nerve blocks (ONBs). While comparative efficacy studies are lacking, botulinum toxin, CGRP antagonists, and ONBs have the most evidence of efficacy in placebo-controlled studies in these patients.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Third-line agents for those who fail treatment with first- and second-line agents include feverfew, <a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">tizanidine</a>, <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>, <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>, <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a>, and <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a>. (See <a class="local">'Second- and third-line agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpharmacologic options</strong> – For patients with chronic migraine who desire nonpharmacologic therapy, we suggest behavioral therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options include relaxation training, thermal biofeedback combined with relaxation training, electromyographic biofeedback, or cognitive-behavioral therapy. As with medications, the choice among these interventions should be individualized. (See <a class="local">'Behavioral and physical therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schwedt TJ. Chronic migraine. BMJ 2014; 348:g1416.</a></li><li><a class="nounderline abstract_t">Torres-Ferrús M, Ursitti F, Alpuente A, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain 2020; 21:42.</a></li><li><a class="nounderline abstract_t">Schwedt TJ, Dodick DW. Advanced neuroimaging of migraine. Lancet Neurol 2009; 8:560.</a></li><li><a class="nounderline abstract_t">Aurora SK. Is chronic migraine one end of a spectrum of migraine or a separate entity? Cephalalgia 2009; 29:597.</a></li><li><a class="nounderline abstract_t">Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010; 30:599.</a></li><li><a class="nounderline abstract_t">Guitera V, Muñoz P, Castillo J, Pascual J. Quality of life in chronic daily headache: a study in a general population. Neurology 2002; 58:1062.</a></li><li><a class="nounderline abstract_t">D'Amico D, Usai S, Grazzi L, et al. Quality of life and disability in primary chronic daily headaches. Neurol Sci 2003; 24 Suppl 2:S97.</a></li><li><a class="nounderline abstract_t">Harwood RH, Sayer AA, Hirschfeld M. Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios. Bull World Health Organ 2004; 82:251.</a></li><li><a class="nounderline abstract_t">Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71:559.</a></li><li><a class="nounderline abstract_t">Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290:2443.</a></li><li><a class="nounderline abstract_t">Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009; 72:S3.</a></li><li><a class="nounderline abstract_t">Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48:1157.</a></li><li><a class="nounderline abstract_t">Lipton RB, Fanning KM, Buse DC, et al. Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study. Neurology 2019; 93:e2224.</a></li><li><a class="nounderline abstract_t">Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003; 106:81.</a></li><li><a class="nounderline abstract_t">Couch JR, Lipton RB, Stewart WF, Scher AI. Head or neck injury increases the risk of chronic daily headache: a population-based study. Neurology 2007; 69:1169.</a></li><li><a class="nounderline abstract_t">Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004; 63:2022.</a></li><li><a class="nounderline abstract_t">Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 2006; 46:1334.</a></li><li><a class="nounderline abstract_t">Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology 2008; 71:848.</a></li><li><a class="nounderline abstract_t">Louter MA, Bosker JE, van Oosterhout WP, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain 2013; 136:3489.</a></li><li><a class="nounderline abstract_t">Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache 2008; 48:16.</a></li><li><a class="nounderline abstract_t">Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 2015; 84:688.</a></li><li><a class="nounderline abstract_t">Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine Progression: A Systematic Review. Headache 2019; 59:306.</a></li><li><a class="nounderline abstract_t">Martin VT, Fanning KM, Serrano D, et al. Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study. Headache 2016; 56:118.</a></li><li><a class="nounderline abstract_t">Reed ML, Fanning KM, Serrano D, et al. Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results. Headache 2015; 55:76.</a></li><li><a class="nounderline abstract_t">Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. Cephalalgia 2020; 40:503.</a></li><li><a class="nounderline abstract_t">Tietjen GE, Brandes JL, Digre KB, et al. High prevalence of somatic symptoms and depression in women with disabling chronic headache. Neurology 2007; 68:134.</a></li><li><a class="nounderline abstract_t">Juang KD, Wang SJ, Fuh JL, et al. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000; 40:818.</a></li><li><a class="nounderline abstract_t">Peres MF, Zukerman E, Young WB, Silberstein SD. Fatigue in chronic migraine patients. Cephalalgia 2002; 22:720.</a></li><li><a class="nounderline abstract_t">Peres MF, Young WB, Kaup AO, et al. Fibromyalgia is common in patients with transformed migraine. Neurology 2001; 57:1326.</a></li><li><a class="nounderline abstract_t">Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache 2005; 45:904.</a></li><li><a class="nounderline abstract_t">Ferrari A, Leone S, Vergoni AV, et al. Similarities and differences between chronic migraine and episodic migraine. Headache 2007; 47:65.</a></li><li><a class="nounderline abstract_t">Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010; 81:428.</a></li><li><a class="nounderline abstract_t">Minen MT, Begasse De Dhaem O, Kroon Van Diest A, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 2016; 87:741.</a></li><li><a class="nounderline abstract_t">Lipton RB, Fanning KM, Buse DC, et al. Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache 2018; 58:933.</a></li><li><a class="nounderline abstract_t">Hovaguimian A, Roth J. Management of chronic migraine. BMJ 2022; 379:e067670.</a></li><li><a class="nounderline abstract_t">Buse DC, Rains JC, Pavlovic JM, et al. Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache 2019; 59:32.</a></li><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med 2006; 354:158.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47:170.</a></li><li><a class="nounderline abstract_t">Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27:814.</a></li><li><a class="nounderline abstract_t">Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23:820.</a></li><li><a class="nounderline abstract_t">Saper JR, Lake AE 3rd, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002; 42:470.</a></li><li><a class="nounderline abstract_t">Yurekli VA, Akhan G, Kutluhan S, et al. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008; 9:37.</a></li><li><a class="nounderline abstract_t">Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003; 61:1753.</a></li><li><a class="nounderline abstract_t">Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010; 112:463.</a></li><li><a class="nounderline abstract_t">Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, et al. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol 2010; 33:35.</a></li><li><a class="nounderline abstract_t">Edvardsson B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. Springerplus 2013; 2:479.</a></li><li><a class="nounderline abstract_t">Pascual-Gómez J, Alañá-García M, Oterino A, et al. [Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate]. Rev Neurol 2008; 47:449.</a></li><li><a class="nounderline abstract_t">Bigal M, Rapoport A, Sheftell F, et al. Memantine in the preventive treatment of refractory migraine. Headache 2008; 48:1337.</a></li><li><a class="nounderline abstract_t">Pavitt S, Gelfand AA, Zorrilla N, et al. Efficacy and Safety of Repetitive Intravenous Sodium Valproate in Pediatric Patients With Refractory Chronic Headache Disorders: A Retrospective Review. Pediatr Neurol 2022; 128:52.</a></li><li><a class="nounderline abstract_t">Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021; 61:1021.</a></li><li><a class="nounderline abstract_t">Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache 2008; 48:201.</a></li><li><a class="nounderline abstract_t">Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45:293.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Stark SR, Lucas SM, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80:1126.</a></li><li><a class="nounderline abstract_t">Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30:793.</a></li><li><a class="nounderline abstract_t">Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30:804.</a></li><li><a class="nounderline abstract_t">Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50:921.</a></li><li><a class="nounderline abstract_t">Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011; 77:1465.</a></li><li><a class="nounderline abstract_t">Lanteri-Minet M, Ducros A, Francois C, et al. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Cephalalgia 2022; 42:1543.</a></li><li><a class="nounderline abstract_t">Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev 2018; 6:CD011616.</a></li><li><a class="nounderline abstract_t">Schoenen J. Botulinum toxin in headache treatment: finally a promising path? Cephalalgia 2010; 30:771.</a></li><li><a class="nounderline abstract_t">Barad M, Ailani J, Hakim SM, et al. Percutaneous Interventional Strategies for Migraine Prevention: A Systematic Review and Practice Guideline. Pain Med 2022; 23:164.</a></li><li><a class="nounderline abstract_t">Zidan A, Roe C, Burke D, Mejico L. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study. J Clin Neurosci 2019; 69:237.</a></li><li><a class="nounderline abstract_t">Masters-Israilov A, Robbins MS. OnabotulinumtoxinA Wear-off Phenomenon in the Treatment of Chronic Migraine. Headache 2019; 59:1753.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 2017; 377:2113.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology 2020; 95:e2487.</a></li><li><a class="nounderline abstract_t">Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019; 394:1030.</a></li><li><a class="nounderline abstract_t">Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16:425.</a></li><li><a class="nounderline abstract_t">Tepper SJ, Ashina M, Reuter U, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia 2020; 40:543.</a></li><li><a class="nounderline abstract_t">Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology 2019; 92:e2250.</a></li><li><a class="nounderline abstract_t">Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology 2019; 92:e2309.</a></li><li><a class="nounderline abstract_t">Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 2018; 38:1611.</a></li><li><a class="nounderline abstract_t">Ashina M, Goadsby PJ, Dodick DW, et al. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. JAMA Neurol 2022; 79:159.</a></li><li><a class="nounderline abstract_t">Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91:e2211.</a></li><li><a class="nounderline abstract_t">Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia 2019; 39:931.</a></li><li><a class="nounderline abstract_t">Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020; 19:814.</a></li><li><a class="nounderline abstract_t">Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020; 94:e1365.</a></li><li><a class="nounderline abstract_t">Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain 2020; 21:120.</a></li><li><a class="nounderline abstract_t">Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 402:775.</a></li><li class="breakAll">QULIPTA (atogepant) tablets, for oral use. US Food &amp; Drug Administration (FDA) approved product information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215206s004lbl.pdf (Accessed on June 07, 2023).</li><li class="breakAll">Eptinezumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761119s002lbl.pdf (Accessed on September 30, 2021).</li><li class="breakAll">Femanezumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761089s013lbl.pdf (Accessed on September 30, 2021).</li><li><a class="nounderline abstract_t">Toni T, Tamanaha R, Newman B, et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci 2021; 42:5373.</a></li><li><a class="nounderline abstract_t">Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine. Pain Med 2021; 22:1857.</a></li><li><a class="nounderline abstract_t">Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. J Pain Palliat Care Pharmacother 2021; 35:1.</a></li><li><a class="nounderline abstract_t">Chowdhury D, Tomar A, Deorari V, et al. Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study. Cephalalgia 2023; 43:3331024221143541.</a></li><li><a class="nounderline abstract_t">Chowdhury D, Mundra A, Datta D, et al. Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial. Cephalalgia 2022; 42:859.</a></li><li><a class="nounderline abstract_t">American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache 2019; 59:1.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Dodick DW, Aurora SK, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry 2015; 86:996.</a></li><li><a class="nounderline abstract_t">Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27:394.</a></li><li><a class="nounderline abstract_t">Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.</a></li><li><a class="nounderline abstract_t">Kroner JW, Peugh J, Kashikar-Zuck SM, et al. Trajectory of Improvement in Children and Adolescents With Chronic Migraine: Results From the Cognitive-Behavioral Therapy and Amitriptyline Trial. J Pain 2017; 18:637.</a></li><li><a class="nounderline abstract_t">Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018; 38:1038.</a></li><li><a class="nounderline abstract_t">Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013; 80:697.</a></li><li><a class="nounderline abstract_t">Di Fiore P, Bussone G, Galli A, et al. Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. Neurol Sci 2017; 38:201.</a></li><li><a class="nounderline abstract_t">Saper JR, Dodick DW, Silberstein SD, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011; 31:271.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2012; 32:1165.</a></li><li><a class="nounderline abstract_t">Schwedt TJ. Occipital nerve stimulation for chronic migraine--interpreting the ONSTIM feasibility trial. Cephalalgia 2011; 31:262.</a></li><li><a class="nounderline abstract_t">Diener HC. Occipital nerve stimulation for chronic migraine: already advised? Cephalalgia 2012; 32:1163.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology 2016; 87:529.</a></li><li><a class="nounderline abstract_t">Diener HC, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 2019; 39:1475.</a></li><li><a class="nounderline abstract_t">Seok JI, Cho HI, Chung CS. From transformed migraine to episodic migraine: reversion factors. Headache 2006; 46:1186.</a></li><li><a class="nounderline abstract_t">Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011; 76:711.</a></li><li><a class="nounderline abstract_t">Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 2017; 18:101.</a></li></ol></div><div id="topicVersionRevision">Topic 3337 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24662044" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32349653" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : From transformation to chronification of migraine: pathophysiological and clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19446275" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Advanced neuroimaging of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228150" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Is chronic migraine one end of a spectrum of migraine or a separate entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19614702" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Global prevalence of chronic migraine: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940693" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Quality of life in chronic daily headache: a study in a general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12811603" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Quality of life and disability in primary chronic daily headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15259253" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711108" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14612481" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lost productive time and cost due to common pain conditions in the US workforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188564" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tracing transformation: chronic migraine classification, progression, and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808500" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31690685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581114" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Factors associated with the onset and remission of chronic daily headache in a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846416" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Head or neck injury increases the risk of chronic daily headache: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596744" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Caffeine as a risk factor for chronic daily headache: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17040331" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Modifiable risk factors for migraine progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779513" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical course in migraine: conceptualizing migraine transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24080152" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cutaneous allodynia as a predictor of migraine chronification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184281" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk factors for headache chronification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25609757" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30589090" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Migraine Progression: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26581563" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25250833" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31635478" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210894" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High prevalence of somatic symptoms and depression in women with disabling chronic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135026" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421157" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fatigue in chronic migraine patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11591860" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fibromyalgia is common in patients with transformed migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985108" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17355496" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Similarities and differences between chronic migraine and episodic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164501" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26733600" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Migraine and its psychiatric comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30024028" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36216384" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Management of chronic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30381821" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16407511" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical practice. Chronic daily headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17300356" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17441971" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510929" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Topiramate in the treatment of chronic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167135" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18231713" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The effect of sodium valproate on chronic daily headache and its subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694042" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20399553" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935409" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pregabalin in the treatment of chronic migraine: an open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24083117" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18985592" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : [Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19031499" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Memantine in the preventive treatment of refractory migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35093793" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and Safety of Repetitive Intravenous Sodium Valproate in Pediatric Patients With Refractory Chronic Headache Disorders: A Retrospective Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34160823" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042229" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15836565" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16178492" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647170" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647171" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20487038" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21956721" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36081276" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29939406" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Botulinum toxins for the prevention of migraine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647167" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Botulinum toxin in headache treatment: finally a promising path?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34382092" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Percutaneous Interventional Strategies for Migraine Prevention: A Systematic Review and Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31327585" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31524289" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : OnabotulinumtoxinA Wear-off Phenomenon in the Treatment of Chronic Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29171818" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Fremanezumab for the Preventive Treatment of Chronic Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32913018" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427046" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28460892" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32216456" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30996060" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30996056" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29984601" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34928306" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30446596" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31104507" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949542" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32209650" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33023473" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37516125" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37516125" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37516125" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37516125" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34409517" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33693863" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33125303" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36739512" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35259978" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30536394" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25500317" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403039" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The triggers or precipitants of the acute migraine attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10993991" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28108386" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Trajectory of Improvement in Children and Adolescents With Chronic Migraine: Results From the Cognitive-Behavioral Therapy and Amitriptyline Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504483" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390177" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28527053" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20861241" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23034698" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20847083" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Occipital nerve stimulation for chronic migraine--interpreting the ONSTIM feasibility trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23059491" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Occipital nerve stimulation for chronic migraine: already advised?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27412146" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31522546" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16866723" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : From transformed migraine to episodic migraine: reversion factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21270413" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Rates, predictors, and consequences of remission from chronic migraine to episodic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28980171" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
